Supervisory Medical Officer
Dr. Linda Scarazzini joined FDA as the new Director of the Division of Pharmacovigilance, in the Office of Pharmacovigilance and Epidemiology within CDER's Office of Surveillance and Epidemiology in May 2011. Her qualifications and leadership experience with drug safety surveillance and development of risk management strategies are a tremendous asset to CDER.
Dr. Scarazzini previously served as the associate vice president of marketed product pharmacovigilance and risk management at Sanofi Aventis Pharmaceuticals. In that role she developed risk communication strategies for health professionals and created and maintained active surveillance and adverse event databases used for post-market drug safety, clinical reviews and studies.
Throughout her 11 years with Sanofi, she held various leadership roles overseeing IND and NDA preparation, managing clinical safety reviews, and developing advanced safety and signal detection surveillance strategies.
Dr. Scarazzini received her pharmacy degree from Philadelphia College of Pharmacy and Science and her medical degree from Temple University School of Medicine. She completed her residency in internal medicine at the Graduate Hospital of the University of Pennsylvania.